# RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

> **NCT01236586** · PHASE1 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Lymphoma
- Brain Neoplasms
- Sarcoma
- Osteosarcoma
- Wilm's Tumor

## Interventions

- **DRUG:** RO4929097
- **DRUG:** Dexamethasone

## Key facts

- **NCT ID:** NCT01236586
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-10-08
- **Primary completion:** 2011-04-13
- **Final completion:** 2011-04-13
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01236586

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01236586, "RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01236586. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*